ArticleNucleic acids research2018
Crystal structure of an anti-CRISPR protein, AcrIIA1.
Article in Nucleic acids research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Dynamic balance of CRISPR-Cas immunity and resistance plasmid anti-immunity mediated by a bifunctional protein AcrIE10.Nature communications · 2026Article
- Genomic islands inNAR genomics and bioinformatics · 2025Article
- AcrIE7 inhibits the CRISPR-Cas system by directly binding to the R-loop single-stranded DNA.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Nano-Polymers as Cas9 Inhibitors.Polymers · 2025Article
- CRISPR in Nucleic Acids Research: the sequel.Nucleic acids research · 2024Article
- An anti-CRISPR that represses its own transcription while blocking Cas9-target DNA binding.Nature communications · 2024Article
- Inhibitory mechanism of CRISPR-Cas9 by AcrIIC4.Nucleic acids research · 2023Article
- CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.ACS infectious diseases · 2023Review
- Type II anti-CRISPR proteins as a new tool for synthetic biology.RNA biology · 2021Review
- Structural basis for inhibition of the type I-F CRISPR-Cas surveillance complex by AcrIF4, AcrIF7 and AcrIF14.Nucleic acids research · 2021Article
- Atomic-scale insights into allosteric inhibition and evolutional rescue mechanism ofComputational and structural biotechnology journal · 2021Article
- Structures and Strategies of Anti-CRISPR-Mediated Immune Suppression.Annual review of microbiology · 2020Review
- Intrinsic disorder is essential for Cas9 inhibition of anti-CRISPR AcrIIA5.Nucleic acids research · 2020Article
- Listeria Phages Induce Cas9 Degradation to Protect Lysogenic Genomes.Cell host & microbe · 2020Article
- Critical Anti-CRISPR Locus Repression by a Bi-functional Cas9 Inhibitor.Cell host & microbe · 2020Article
- Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.Annual review of biochemistry · 2020Review
- Machine learning predicts new anti-CRISPR proteins.Nucleic acids research · 2020Article
- Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies.Nature methods · 2020Review
- Inhibition mechanisms of AcrF9, AcrF8, and AcrF6 against type I-F CRISPR-Cas complex revealed by cryo-EM.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Structural insight into multistage inhibition of CRISPR-Cas12a by AcrVA4.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) proteins provide bacteria with RNA-based adaptive immunity against phage infection. To counteract this defense mechanism, phages evolved anti-CRISPR (Acr) proteins that inactivate the CRISPR-Cas systems. AcrIIA1, encoded by Listeria monocytogenes prophages, is the most prevalent among the Acr proteins targeting type II-A CRISPR-Cas systems and has been used as a marker to identify other Acr proteins. Here, we report the crystal structure of AcrIIA1 and its RNA-binding affinity. AcrIIA1 forms a dimer with a novel two helical-domain architecture. The N-terminal domain of AcrIIA1 exhibits a helix-turn-helix motif similar to transcriptional factors. When overexpressed in Escherichia coli, AcrIIA1 associates with RNAs, suggesting that AcrIIA1 functions via nucleic acid recognition. Taken together, the unique structural and functional features of AcrIIA1 suggest its distinct mode of Acr activity, expanding the diversity of the inhibitory mechanisms employed by Acr proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.